Activating the Patient's Immune System to Fight Cancer Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable safety and tolerability profile. Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment. Building on successful clinical studies which have provided deep mechanistic insights into the tumor biology and the human immune systems, Targovax is researching circular RNA (circRNA) as novel cancer medicines. In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, expected to enter the clinic in an enhanced format in the second half of 2022. Together this provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.
View Top Employees from Targovax ASAWebsite | http://www.targovax.com |
Revenue | $8 million |
Funding | $42.6 million |
Employees | 37 (16 on RocketReach) |
Founded | 2010 |
Phone | (472) 139-8810 |
Industry | Biotechnology, Biotechnology Research, Pharmaceuticals, Healthcare, Drug Manufacturing & Research |
Web Rank | 7 Million |
Keywords | Targovax, Small And Medium Enterprises Conference Dnb |
Competitors | ALX Oncology, DNAtrix, EpicentRx, Inc., Leap Therapeutics, PsiOxus |
SIC | SIC Code 28 Companies, SIC Code 283 Companies, SIC Code 2834 Companies |
NAICS | NAICS Code 54 Companies, NAICS Code 5417 Companies, NAICS Code 541711 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies |
Looking for a particular Targovax ASA employee's phone or email?
The Targovax ASA annual revenue was $8 million in 2023.
Erik Wiklund is the CEO of Targovax ASA.
16 people are employed at Targovax ASA.
The NAICS codes for Targovax ASA are [54, 5417, 541711, 541, 54171].
The SIC codes for Targovax ASA are [28, 283, 2834].